Market Intelligence, Clinical Progress, and High-Purity Reagents for NSCLC and Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KRAS G12C drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Mutant Antigen (G12C) | KRAS G12C Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW ~21 kDa. Cysteine 12 intact for covalent assay. |
View KRAS G12C Products |
| WT Antigen | KRAS Wild-Type Protein For selectivity counter-screening. >95% purity. Sequence Verified. |
View KRAS Products |
| Resistance Mutant Panel | KRAS G12D / G12V / Q61H Mutant Proteins Pre-validated resistance variants for combination therapy screening. |
View KRAS G12D Products |
| Gene Delivery | KRAS G12C Promise-ORF / Lentivirus Full-length ORF for stable isogenic cell line construction. |
View KRAS G12C Products |
| Benchmark Ab | Anti-KRAS G12C Antibody (Recombinant) Sequence-verified positive control for mutant-specific detection. |
View KRAS G12C Products |
| Validator | KRAS siRNA Set For target specificity verification and knockdown validation. |
View KRAS Products |
| Related Target: EGFR | EGFR Protein Upstream regulator; compensatory pathway activation analysis. |
View EGFR Products |
| Related Target: SHP2 | SHP2 (PTPN11) Protein Parallel pathway targeting for combination resistance strategies. |
View SHP2 Products |
| Related Target: SOS1 | SOS1 Protein Synergistic pathway partner; critical for guanine nucleotide exchange assays. |
View SOS1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant vs WT Selectivity Screening | Purified KRAS G12C and KRAS WT proteins with identical production standards (E. coli/HEK293) for direct comparative binding assays and off-target liability assessment. |
| Drug Resistance Profiling | Pre-made G12D, G12V, Q61H mutants available for parallel screening of inhibitor cross-reactivity and resistance mechanism studies. |
| Off-target RAS Family Screening | NRAS and HRAS wild-type proteins available for selectivity panels to eliminate pan-RAS inhibition risks. |
| Covalent Inhibitor Validation | High-purity cysteine-containing mutant protein (G12C) maintained in reducing conditions to preserve Cys12 accessibility for covalent binding assays. |
| Lack of Controls | Sequence-verified wild-type and mutant isoforms for assay normalization and specificity confirmation. |
Live KRAS G12C R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
Following the FDA approval of Sotorasib (Amgen) and Adagrasib (Mirati/BMS), the KRAS G12C inhibitor landscape has shifted toward combination strategies and next-generation inhibitors. The emergence of intrinsic and acquired resistance mutations (Y96C, R68S, H95D/Q) and parallel pathway activation (NRAS, BRAF, EGFR amplification) necessitates comprehensive mutant panels for preclinical validation. Current development focuses on overcoming the limited duration of response observed with monotherapy through rational combinations with EGFR, SHP2, and immune checkpoint inhibitors. The next wave includes non-covalent inhibitors (e.g., Revolution Medicines' RMC-6291), PROTAC degraders (Arvinas, Cullgen), and TCR-T/bispecific approaches targeting KRAS G12C peptide-MHC complexes. Major players like Roche, Johnson & Johnson, and Boehringer Ingelheim are advancing next-generation covalent and non-covalent molecules to address acquired resistance and expand efficacy into colorectal and pancreatic cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Covalent SMIs (1st Gen) | Amgen (Sotorasib), Mirati (Adagrasib) | NSCLC, CRC | Selectivity Assay (G12C vs WT) - Need high purity mutant and WT proteins |
| Next-Gen Covalent | Johnson & Johnson, Roche | Solid Tumors | Covalent binding kinetics - Need properly folded G12C with accessible Cys12 |
| Non-covalent Inhibitors | Revolution Medicines, Boehringer Ingelheim | NSCLC, PDAC | Binding affinity assays - Need thermostable mutant proteins |
| PROTACs | Arvinas, Cullgen | Refractory Tumors | Ternary complex formation - Need high purity antigens for pulldown |
| Combination Partners | Various | Multiple | EGFR/SHP2 co-targeting assays - Need pathway protein panel |
| TCR-T / Bispecifics | Immunocore | Advanced Solid Tumors | Peptide-MHC binding - Need precise sequence-verified antigens |